Cargando…
Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients
BACKGROUND: The European baseline series (EBS) of contact allergens is subject to change. An allergen is considered for inclusion when routine patch testing of patients with suspected contact dermatitis results in ≥0.5% prevalence rate. OBJECTIVES: We aimed to determine the frequency of sensitizatio...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796124/ https://www.ncbi.nlm.nih.gov/pubmed/35736503 http://dx.doi.org/10.1111/cod.14178 |
_version_ | 1784860412119875584 |
---|---|
author | Bizjak, Mojca Adamič, Katja Bajrovič, Nissera Eržen, Renato Jošt, Maja Kopač, Peter Košnik, Mitja Lalek, Nika Zidarn, Mihaela Dinevski, Dejan |
author_facet | Bizjak, Mojca Adamič, Katja Bajrovič, Nissera Eržen, Renato Jošt, Maja Kopač, Peter Košnik, Mitja Lalek, Nika Zidarn, Mihaela Dinevski, Dejan |
author_sort | Bizjak, Mojca |
collection | PubMed |
description | BACKGROUND: The European baseline series (EBS) of contact allergens is subject to change. An allergen is considered for inclusion when routine patch testing of patients with suspected contact dermatitis results in ≥0.5% prevalence rate. OBJECTIVES: We aimed to determine the frequency of sensitizations to 30 EBS allergens and 10 locally added allergens. Additionally, we assessed the strength and evolution of reactions to all tested allergens and co‐reactivity of additional allergens. METHODS: Patch testing with our baseline series of 40 allergens was done in 748 consecutive adults. Tests were applied to the upper back and removed by patients after 48 h. Readings were done on Day 3 (D3) and D6 or D7 (D6/7). Positive reactions fulfilled the criteria of at least one plus (+) reaction. A retrospective analysis was done. RESULTS: Eight allergens not listed in the EBS had ≥0.5% prevalence rate (i.e., cocamidopropyl betaine, thiomersal, disperse blue mix 106/124, 2‐bromo‐2‐nitropropane‐1,3‐diol, diazolidinyl urea, propylene glycol, Compositae mix II and dexamethasone‐21‐phosphate), and 16.6% of positive reactions would have been missed without D6/7 readings. CONCLUSION: We propose further studies to evaluate whether cocamidopropyl betaine, disperse blue mix 106/124, 2‐bromo‐2‐nitropropane‐1,3‐diol, diazolidinyl urea and Compositae mix II need to be added to the EBS. |
format | Online Article Text |
id | pubmed-9796124 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-97961242022-12-30 Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients Bizjak, Mojca Adamič, Katja Bajrovič, Nissera Eržen, Renato Jošt, Maja Kopač, Peter Košnik, Mitja Lalek, Nika Zidarn, Mihaela Dinevski, Dejan Contact Dermatitis Original Articles BACKGROUND: The European baseline series (EBS) of contact allergens is subject to change. An allergen is considered for inclusion when routine patch testing of patients with suspected contact dermatitis results in ≥0.5% prevalence rate. OBJECTIVES: We aimed to determine the frequency of sensitizations to 30 EBS allergens and 10 locally added allergens. Additionally, we assessed the strength and evolution of reactions to all tested allergens and co‐reactivity of additional allergens. METHODS: Patch testing with our baseline series of 40 allergens was done in 748 consecutive adults. Tests were applied to the upper back and removed by patients after 48 h. Readings were done on Day 3 (D3) and D6 or D7 (D6/7). Positive reactions fulfilled the criteria of at least one plus (+) reaction. A retrospective analysis was done. RESULTS: Eight allergens not listed in the EBS had ≥0.5% prevalence rate (i.e., cocamidopropyl betaine, thiomersal, disperse blue mix 106/124, 2‐bromo‐2‐nitropropane‐1,3‐diol, diazolidinyl urea, propylene glycol, Compositae mix II and dexamethasone‐21‐phosphate), and 16.6% of positive reactions would have been missed without D6/7 readings. CONCLUSION: We propose further studies to evaluate whether cocamidopropyl betaine, disperse blue mix 106/124, 2‐bromo‐2‐nitropropane‐1,3‐diol, diazolidinyl urea and Compositae mix II need to be added to the EBS. Blackwell Publishing Ltd 2022-07-08 2022-11 /pmc/articles/PMC9796124/ /pubmed/35736503 http://dx.doi.org/10.1111/cod.14178 Text en © 2022 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Bizjak, Mojca Adamič, Katja Bajrovič, Nissera Eržen, Renato Jošt, Maja Kopač, Peter Košnik, Mitja Lalek, Nika Zidarn, Mihaela Dinevski, Dejan Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients |
title | Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients |
title_full | Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients |
title_fullStr | Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients |
title_full_unstemmed | Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients |
title_short | Patch testing with the European baseline series and 10 added allergens: Single‐centre study of 748 patients |
title_sort | patch testing with the european baseline series and 10 added allergens: single‐centre study of 748 patients |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9796124/ https://www.ncbi.nlm.nih.gov/pubmed/35736503 http://dx.doi.org/10.1111/cod.14178 |
work_keys_str_mv | AT bizjakmojca patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients AT adamickatja patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients AT bajrovicnissera patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients AT erzenrenato patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients AT jostmaja patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients AT kopacpeter patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients AT kosnikmitja patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients AT laleknika patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients AT zidarnmihaela patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients AT dinevskidejan patchtestingwiththeeuropeanbaselineseriesand10addedallergenssinglecentrestudyof748patients |